Entheon Biomedical Past Earnings Performance
Past criteria checks 0/6
Entheon Biomedical has been growing earnings at an average annual rate of 44.3%, while the Biotechs industry saw earnings growing at 19.7% annually. Revenues have been growing at an average rate of 62.3% per year.
Key information
44.3%
Earnings growth rate
64.3%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 62.3% |
| Return on equity | -115.0% |
| Net Margin | n/a |
| Last Earnings Update | 31 May 2024 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How Entheon Biomedical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 May 24 | 0 | 0 | 0 | 0 |
| 29 Feb 24 | 0 | 0 | 0 | 0 |
| 30 Nov 23 | 0 | 0 | 1 | 0 |
| 31 Aug 23 | 0 | 0 | 1 | 0 |
| 31 May 23 | 0 | 0 | 1 | 0 |
| 28 Feb 23 | 0 | -1 | 2 | 1 |
| 30 Nov 22 | 0 | -2 | 3 | 1 |
| 31 Aug 22 | 0 | -3 | 4 | 1 |
| 31 May 22 | 0 | -5 | 4 | 1 |
| 28 Feb 22 | 0 | -7 | 5 | 1 |
| 30 Nov 21 | 0 | -8 | 7 | 1 |
| 31 Aug 21 | 0 | -10 | 6 | 1 |
| 31 May 21 | 0 | -9 | 5 | 1 |
| 28 Feb 21 | 0 | -7 | 3 | 1 |
| 30 Nov 20 | 0 | -4 | 1 | 0 |
Quality Earnings: ENTB.F is currently unprofitable.
Growing Profit Margin: ENTB.F is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ENTB.F is unprofitable, but has reduced losses over the past 5 years at a rate of 44.3% per year.
Accelerating Growth: Unable to compare ENTB.F's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ENTB.F is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (0.5%).
Return on Equity
High ROE: ENTB.F has a negative Return on Equity (-114.96%), as it is currently unprofitable.